2025 – Page 72 – Talk Bio

Graft-Versus-Host Disease (GvHD), Microbiome Therapy, MaaT013, Acute GvHD, Steroid-Resistant GvHD, Faecal Microbiota Transplantation, Precision Nutrition

Revival of Dormant Antipsychotic Class: LB Pharma’s Phase II Success with LB-102

4 months ago talkbio0Tagged Antipsychotic Agents, benzamide, LB-102, Pharma, Phase 2 Clinical Trials, Pounds, Schizophrenia

LB Pharma, LB-102, Antipsychotic drugs, Schizophrenia treatment, Phase II clinical trials, Benzamide antipsychotics

Transcarent Acquires Accolade for $621 Million in Strategic Healthcare Deal

4 months ago talkbio0Tagged Accolade, AI-powered, Health care facility, healthcare acquisition, Healthcare technology, Transcarent

Transcarent, Accolade, healthcare acquisition, personalized healthcare, AI-powered healthcare, healthcare technology

Revance Therapeutics Faces Competing Buyout Offers: Teoxane SA Outbids Crown Laboratories

4 months ago talkbio0Tagged Biotechnology, Crown Laboratories, Industry, Revance, sulfanilamide, Teoxane

Revance Therapeutics, Teoxane SA, Crown Laboratories, buyout offers, merger agreement, biotechnology, skincare industry

FDA Mandates Guillain-Barré Syndrome Warning for Pfizer and GSK RSV Vaccines

4 months ago talkbio0Tagged Abrysvo, Arexvy, Cautionary Warning, Guillain-Barré syndrome, Pfizer, Respiratory syncytial virus, SmithKline Beecham, United States Food and Drug Administration, Vaccines

RSV vaccines, Guillain-Barré syndrome, FDA warning, Pfizer, GSK, Abrysvo, Arexvy

Tenvie Therapeutics Launches with $200 Million to Revolutionize Neurological Disease Treatment

4 months ago talkbio0Tagged Arch of foot, Denali, F-Prime Capital, Mubadala, Neurological diseases, Partner in relationship, small molecule therapies, Tenvie, venture

Tenvie Therapeutics, neurological diseases, small molecule therapies, Denali Therapeutics, ARCH Venture Partners, F-Prime Capital, Mubadala Capital